

OMTO, Volume 5

Supplemental Information

**Preclinical Safety Studies of Enadenotucirev,
a Chimeric Group B Human-Specific Oncolytic**

Adenovirus

Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R. Duffy, Simon Alvis, Brian Champion, André Lieber, Terry Hermiston, Len W. Seymour, John Beadle, and Kerry Fisher

Supplementary Data S1. Haematology and cytokine tables supplementary to Figure 3c following intravenous injection of 1×10^{11} particles enadenotucirev (EnAd) n=5; or replication incompetent enadenotucirev (EnAdCJ132) or saline.

a Hematology parameters of CD46 transgenic mice following the administration of a single dose of EnAd, EnAdCJ132, and Virus buffer (n = 5/group). Values represent mean \pm standard deviation.

Parameter	Time Point	Treatment		
		Buffer	EnAd	EnAd1CJ132
WBC, $10^3/\mu\text{L}$	Pre-dosing ^a	9.50 \pm 2.06	9.50 \pm 2.06	9.50 \pm 2.06
	24 hrs post	8.04 \pm 2.18	0.83 \pm 0.22	0.93 \pm 0.31
	72 hrs post	9.37 \pm 0.81	3.17 \pm 0.54	3.41 \pm 1.56
RBC, $10^6/\mu\text{L}$	Pre-dosing ^a	9.01 \pm 0.41	9.01 \pm 0.41	9.01 \pm 0.41
	24 hrs post	7.82 \pm 0.63	7.62 \pm 0.70	8.92 \pm 0.46
	72 hrs post	7.79 \pm 0.42	6.59 \pm 1.11	7.27 \pm 0.65
Platelets, $10^3/\mu\text{L}$	Pre-dosing ^b	1,071 \pm 132	1,071 \pm 132	1,071 \pm 132
	24 hrs post	1,040 \pm 122	702 \pm 230	747 \pm 165
	72 hrs post	1,058 \pm 108	442 \pm 203	544 \pm 121
Hemoglobin, g/dL	Pre-dosing ^a	15.0 \pm 0.7	15.0 \pm 0.7	15.0 \pm 0.7
	24 hrs post	13.1 \pm 1.4	12.3 \pm 1.4	14.4 \pm 0.5
	72 hrs post	12.6 \pm 0.8	11.0 \pm 1.8	12.5 \pm 1.2
Hematocrit, %	Pre-dosing	46.7 \pm 1.1 ^d	45.0 \pm 3.1	44.8 \pm 1.2
	24 hrs post	35.5 \pm 6.3	36.3 \pm 3.8	43.8 \pm 2.7
	72 hrs post	37.1 \pm 2.9	33.2 \pm 1.2	35.3 \pm 3.9
Alanine aminotransferase (sGPT), IU/L	Pre-dosing ^c	76 \pm 29	76 \pm 29	76 \pm 29
	72 hrs post	52 \pm 44 ^d	107 \pm 30	269 \pm 24 ^d

a) Pooling of mice from all groups, n = 15 (Buffer, n = 5; ColoAd1, n = 5; ColoAd1CJ132, n = 5).

b) Pooling of mice from all groups, n = 14 (Buffer, n = 4; ColoAd1, n = 5; ColoAd1CJ132, n = 5).

c) Pooling of mice from all groups, n = 6.

d) N = 4.

b

Chemokine	Time Point	Treatment		
		Buffer	EnAd1	EnAdCJ132
IL-12p70	Pre-dosing ^a	115.1 \pm 25.9	115.1 \pm 25.9	115.1 \pm 25.9
	1 hr post	105.3 \pm 27.0	101.9 \pm 21.2	117.7 \pm 17.9
	6 hrs post	90.1 \pm 28.5	104.0 \pm 24.3	106.4 \pm 31.8
	24 hrs post	93.6 \pm 15.5	73.0 \pm 27.0	109.9 \pm 13.8
TNF-a	Pre-dosing ^a	31.7 \pm 23.0	31.7 \pm 23.0	31.7 \pm 23.0
	1 hr post	45.6 \pm 15.6	91.7 \pm 28.1	76.8 \pm 21.1
	6 hrs post	31.4 \pm 7.9	438.7 \pm 202.0	261.7 \pm 68.3
	24 hrs post	20.8 \pm 24.2	68.5 \pm 15.2	82.6 \pm 21.2
IFN-a	Pre-dosing ^a	13.5 \pm 2.2	13.5 \pm 2.2	13.5 \pm 2.2
	1 hr post	14.0 \pm 2.7	14.7 \pm 2.1	16.1 \pm 2.1
	6 hrs post	12.4 \pm 2.5	108.2 \pm 160.0	35.7 \pm 9.3
	24 hrs post	12.5 \pm 2.8	48.2 \pm 12.8	55.8 \pm 22.0
MCP-1	Pre-dosing ^a	10 \pm 28	10 \pm 28	10 \pm 28
	1 hr post	58 \pm 68	1,824 \pm 269	640 \pm 318
	6 hrs post	96 \pm 68	32,663 \pm 31,374	19,293 \pm 11,443
	24 hrs post	453 \pm 214	6,438 \pm 1,457	6,856 \pm 306
IL-10	Pre-dosing ^a	0 \pm 0 ^b	0 \pm 0 ^b	0 \pm 0 ^b
	1 hr post	0 \pm 0 ^b	0 \pm 0 ^b	0 \pm 0 ^b
	6 hrs post	0 \pm 0 ^b	0 \pm 0 ^b	0 \pm 0 ^b
	24 hrs post	0 \pm 0 ^b	0 \pm 0 ^b	0 \pm 0 ^b
IL-6	Pre-dosing ^a	17 \pm 11	17 \pm 11	17 \pm 11
	1 hr post	8 \pm 6	159 \pm 39	109 \pm 62
	6 hrs post	19 \pm 7	2,652 \pm 1,334	1,196 \pm 597
	24 hrs post	46 \pm 36	63 \pm 32	70 \pm 41

^aPooling of mice from all groups; ^blevels below limit of detection.